SCHEMBL2804209

SCHEMBL2804209

CC(C)(C)c1ccc(NC(=O)N2CCc3c(cnc4[nH]ncc34)C2)cc1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 7/20 0.54
PAK1 Q13153 4/20 0.48
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPK1 P28482 1/20 0.46
CNR2 P34972 2/20 0.45
PANK3 Q9H999 1/20 0.45
TRPA1 O75762 1/20 0.44
KCNH2 Q12809 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 1/20 0.44
PKM P14618 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
ROCK2 O75116 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12342043 0.87 MEN1 (0.55) TRPV1PAK1MAPTMAPK1LMNA
SCHEMBL2486602 0.86 RAB9A (0.55) TRPV1PAK1KDM4EMAPK1ALDH1A1
SCHEMBL2802864 0.86 KIT (0.46) PAK1MAPK1CNR2ALDH1A1ROCK2
SCHEMBL2804129 0.85 NAMPT (0.52) TRPV1PAK1MAPK1LMNAROCK2
SCHEMBL2803935 0.85 NPC1 (0.58) TRPV1PAK1MAPTALDH1A1LMNA
SCHEMBL2802916 0.84 NAMPT (0.48) PAK1
SCHEMBL2802235 0.84 NPC1 (0.60) PAK1MAPTALDH1A1LMNA
SCHEMBL2802809 0.82 PDGFRB (0.62) TRPV1PAK1ROCK2
SCHEMBL2805093 0.82 PAK1 (0.44) TRPV1PAK1ROCK2
SCHEMBL2805547 0.82 TRPV1 (0.56) TRPV1PAK1MAPTALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 TRPV1 1732/4885PAK1 717/4885MAPT 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.